Asif Sharfuddin, MD
Nephrology · Indianapolis, INNPI 1942254065
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,750 of the $5,321 with a category attached, or 70.5%. Pierre Fabre Pharmaceuticals, Inc. accounts for 94.0% of it on its own, with 2 other manufacturers making up the rest.
Across 9 payments — averaging $591.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pierre Fabre Pharmaceuticals, Inc.$5K
- CSL Behring$316
- Travere Therapeutics, Inc.$6
Across 6 payments — averaging $23,457 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$141K
What the payments were for
- Speaking & faculty fees$3,75070%
- Travel & lodging$1,01219%
- Food & beverage$55210%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pierre Fabre Pharmaceuticals, Inc. | 6 | $4,999 |
| CSL Behring | 1 | $316 |
| Travere Therapeutics, Inc. | 2 | $6 |
How this compares
$5,321 in reported general payments places this provider in the 80th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AranespDarbepoetin Alfa In Polysorbat | 24 | $91,055 |
| Cinacalcet Hcl | 138 | $36,928 |
| Tacrolimus | 181 | $15,946 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $15,383 |
| Sirolimus | 59 | $12,860 |
| Mycophenolic AcidMycophenolate Sodium | 34 | $6,124 |
| ProcritEpoetin Alfa | 12 | $6,046 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,155 |
| Mycophenolate Mofetil | 76 | $3,366 |
| Midodrine Hcl | 46 | $2,796 |
| Valganciclovir Hcl | 21 | $2,621 |
| Famotidine | 137 | $2,154 |
| Pantoprazole Sodium | 128 | $1,936 |
| Lamivudine HbvLamivudine | 11 | $1,882 |
| Potassium Chloride | 20 | $1,865 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Indianapolis
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Bruce MolitorisIndianapolis$108K
- Michael KrausIndianapolis$92K
- Muhammad MujtabaIndianapolis$71K
- Simit DoshiIndianapolis$63K
- Arjun SinhaIndianapolis$50K
- Brent MillerIndianapolis$46K
- James ElliottIndianapolis$37K
- Nupur GuptaIndianapolis$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.